HeartSciences Inc. (HSCSW) stock
Close on Oct 30, 2026Market cap $15.89MP/E –Yield 0.00%
HeartSciences Inc. reported revenue of $4.52K for the twelve months to Jul 31, 2026. Free cash flow was -$7.43M. At the latest close the market valued the company at $15.89M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 31, 2026
Valuation
- Market cap
- $15.89M
- P/E ratio
- –
- Price to sales
- 3515.95
- Price to book
- –
- Dividend yield
- 0.00%
- Free cash flow yield
- –
Fundamentals
- Revenue
- $4.52K
- Net income
- -$10.26M
- EPS, diluted
- -$3.22
- Free cash flow
- -$7.43M
- Book value per share
- -$0.55
- Diluted shares
- 4M
Trading
- Next earnings
- Dec 14, 2026 (estimated, after the close)
- Previous close
- $0.10
- Open
- $0.10
- Day's range
- $0.07 – $0.13
- Volume
- 18,147
- Average volume (20 days)
- 7,262
- Beta (5 years)
- 1.83
- 52-week range
- $1.63 – $5.25
- RSI (14 days)
- 47.7
- Volatility (1 year)
- 108.5%
- Relative volume
- 0.30×
- WACC
- 14.1%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | HSCSW | S&P 500 | Difference | HSCSW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -12.5% | -0.9% | −11.6 pts | ||
| 3 months | +81.8% | +2.1% | +79.7 pts | ||
| Year to date | -0.3% | +11.7% | −12.0 pts | ||
| 1 year | +15.5% | +12.4% | +3.1 pts | ||
| 3 years | +133.3% | +88.6% | +44.8 pts | +32.6% | +23.5% |
Six years at a glance
Fiscal years 2021 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases HeartSciences filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Update
- Update
- Results
About HeartSciences
Finance Services
HeartSciences is a medical technology company that develops artificial intelligence-driven electrocardiography solutions to enhance cardiac care. Its flagship product is MyoVista Insights, a cloud-based, device-agnostic ECG data management platform designed to organize clinical workflows and integrate multi-vendor AI-ECG algorithms. The company also develops the MyoVista wavECG device, a point-of-care resting twelve-lead ECG system engineered to host embedded cardiac analysis algorithms. HeartSciences serves healthcare providers ranging from primary care settings to large hospital systems and cardiology practices seeking modernized ECG infrastructure and risk assessment tools.
Company profile, executives and historyHeartSciences stock: common questions
What is HeartSciences's stock price?
HSCSW closed at $0.07 on Oct 30, 2026, down 30.62% on the day. Over the past 52 weeks it traded between $1.63 and $5.25.
What is HeartSciences's market cap?
HeartSciences was worth $15.89M at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is HSCSW's P/E ratio?
HeartSciences lost money over the twelve months to Jul 31, 2026 (diluted EPS -$3.22), so it has no meaningful P/E ratio.
How much revenue does HeartSciences make?
HeartSciences reported revenue of $4.52K for the twelve months to Jul 31, 2026.
Does HeartSciences pay a dividend?
No. HeartSciences has not paid a cash dividend over the last twelve months.
When does HeartSciences report earnings next?
HeartSciences is expected to report Q2 FY2027 results on Dec 14, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has HSCSW stock performed over the past year?
Including dividends, HSCSW returned +15.5% over the past year, against +12.4% for the S&P 500.
Who are HeartSciences's competitors?
Companies most similar to HeartSciences by business, industry and size include CRSF, COSG, SGRX, NBND, ALP.